Association of COMT rs4680 Genotype With Chronic Neuropathic Pain Experience in Patients With Sickle Cell Disease.
Abigail R Islam, Gebre-Egziabher Kiros, Rachael O Ajiboye and 7 others
PMID 39734110WHAT IT FOUND
In 184 adults with sickle cell disease, COMT rs4680 genotype showed no significant association with S-LANSS or NPSI neuropathic pain scores.
Key findings
01S-LANSS neuropathic pain scores were 11.3 for Val/Val, 10.4 for Val/Met, and 9.4 for Met/Met, and neither genotype (p = .48) nor additive Met allele (p = .23) was significantly associated.
02NPSI neuropathic pain scores were 36.1 for Val/Val, 36.0 for Val/Met, and 33.7 for Met/Met, and neither genotype (p = .90) nor additive Met allele (p = .73) was significantly associated.
03The study included 184 adults with sickle cell disease, but only 17 had the Met/Met genotype, which limited power.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The sample was recruited by sequential convenience sampling, so it may not represent all adults with sickle cell disease. Only 17 of 184 participants had the Met/Met genotype, which limited power. The study used self-report neuropathic pain questionnaires, S-LANSS and NPSI, and the authors called the tools limited. The study focused on one COMT SNP, rs4680, and did not test other COMT variants or haplotypes. The sample size came from the available sickle cell disease sample in a larger study, not from a power calculation for this genotype-pain question.
Declared interests
The authors declared no known competing financial interests or personal relationships, and the article is marked as supported by NIH extramural research funding.
The easy way to misread this
Do not conclude that COMT rs4680 genotype can guide neuropathic pain assessment or management in sickle cell disease. The study found no significant association with S-LANSS or NPSI scores, and only 17 of 184 participants had the Met/Met genotype.